IP Library Granted Patent US 9,309,232
Granted Patent B2
US 9,309,232 · App. 14/390,548 · Granted Apr 12, 2016

Synthesis of novel inhibitors of isoprenoid biosynthesis

Inventors: Timothy J. Hagen (Lisle, IL); Zheng Zhang (Dekalb, IL); Zachary Lazowski (Dekalb, IL); Michael Clare (Skokie, IL); Darren W. Begley (Seattle, WA)
Assignees: Board of Trustees of Northern Illinois University; Beryllium Discovery Corp.
C07D405/12A61K31/4164A61K31/4174A61K31/506A61K45/06C07D233/64C07D239/47C07D401/12C07D403/06C07D403/12C07D405/06C07D417/12C07F9/657136C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,309,232
App. No.
14/390,548
Granted
Apr 12, 2016
Kind
B2
Abstract

Antibacterial IspF inhibitor compounds and compositions are described. Methods include administering described compounds and compositions to treat bacterial or parasitic infections and to inhibit or parasite or bacterial growth.

Claims (38)

1. A compound of Formula II:

or a compound of Formula III:

or a pharmaceutically acceptable salt thereof, wherein

R 1 is H or lower alkyl;

R 2 is H or lower alkyl; and

R 3 is biphenyl, pyridine, pyrimidine, oxazine, oxathiazine,

 or

 each of which may be optionally substituted or R 3 is substituted alkylaryl;

wherein the alkyl of the alkylaryl is comprised of 2 to 8 carbon atoms.

2. The compound of claim 1 of Formula II:

or a pharmaceutically acceptable salt thereof, wherein

R 1 is H or lower alkyl;

R 2 is H or lower alkyl; and

R 3 is substituted alkylaryl or optionally substituted biphenyl, pyridine, pyrimidine, oxazine, or oxathiazine;

wherein the alkyl of the alkylaryl is comprised of 2 to 8 carbon atoms.

3. The compound of claim 1 of Formula III:

or a pharmaceutically acceptable salt thereof, wherein

R 1 is H or lower alkyl;

R 2 is H or lower alkyl; and

R 3 is substituted alkylaryl, or optionally substituted biphenyl, pyridine, pyrimidine, oxazine, or oxathiazine;

wherein the alkyl of the alkylaryl is comprised of 2 to 8 carbon atoms.

4. The pharmaceutically acceptable salt of claim 2 which is

5. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1 and a pharmaceutically acceptable carrier.

6. A method of treating a bacterial infection, the method comprising administering a therapeutically effective amount of the compound according to claim 1 , wherein the bacterial infection is a Burkholderia infection.

7. A method of treating a bacterial infection, the method comprising administering a therapeutically effective amount of the compound according to claim 1 , wherein the bacterial infection is a Mycobacterium infection.

8. A method of treating tuberculosis, the method comprising administering a therapeutically effective amount of the compound, of claim 1 .

9. A method of treating malaria the method comprising administering a therapeutically effective amount of the compound of claim 1 .

10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen.

11. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen.

12. The compound of claim 1 of Formula II:

or a compound of Formula III:

or a pharmaceutically acceptable salt thereof, wherein

R 3 is substituted alkylaryl, or optionally substituted pyridine, pyrimidine, oxazine, or oxathiazine, and

wherein the alkyl of the alkylaryl is comprised of 2 to 8 carbon atoms.

13. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 is a substituted ethylaryl.

14. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R 1 and R 2 are hydrogen, and

R 3 is a substituted ethylaryl.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2021
From: BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY
To: NORTHERN ILLINOIS RESEARCH FOUNDATION
Reel/Frame 057712/0237 →
CHANGE OF NAME Recorded Jan 11, 2016
From: EMERALD BIOSTRUCTURES, INC.
To: BERYLLIUM DISCOVERY CORP.
Reel/Frame 037483/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2014
From: HAGEN, TIMOTHY J.; ZHANG, ZHENG; LAZOWSKI, ZACHARY; CLARE, MICHAEL; BEGLEY, DARREN W.
To: BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY; CLARE ASSOCIATES, LLC; EMERALD BIOSTRUCTURES, INC.
Reel/Frame 033883/0072 →
Continuity (4)
Provisional Application 61637642 · Apr 24, 2012
Provisional Application 61701269 · Sep 14, 2012
Provisional Application 61703145 · Sep 19, 2012
Related Publication 20150175582A1 · Jun 25, 2015